Cervical cancer
Conditions
Interventions
Group of PEG-rhG-CSF Prevention:Prophylactic use of PEG-rhG-CSF
group of PEG-rhG-CSF treatment:Therapeutic application of PEG-rhG-CSF (Xinruibai)
group of rhG-CSF treatment:Granulocyte Colony-Stimulating Factor Injection
Sponsors
HenanCancerHospital
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with cervical cancer confirmed by histopathology; 2. Age >= 18 years, =1.5×10^9/L, platelet count (PLT) >=80×10^9/L, hemoglobin (Hb) >=75 g/L, white blood cell count (WBC) >=3×10^9/L, and no bleeding tendency; 7. No signs of bone metastasis were detected before treatment; 8. The subjects voluntarily participated in this clinical trial and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Have undergone hematopoietic stem cell transplantation or bone marrow transplantation; 2.During the current treatment course, PEG-rhG-CSF or rhG-CSF is used to prevent ANC reduction; 3.Currently participating in other drug clinical trials; 4.Currently has an uncontrollable infection, or has received systemic antibiotic treatment within 72 hours before chemotherapy; 5.Liver function tests total bilirubin (TBIL), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) are all >2.5 times the upper limit of normal: if caused by liver metastasis, the above indicators are >5 times the upper limit of normal; 6.Renal function test: serum creatinine (Cr) > 1.5 times the upper limit of normal; 7.Individuals allergic to this product or other biologics derived from genetically engineered Escherichia coli. 8.Women who are pregnant or breastfeeding, or patients of childbearing potential who are unwilling to use contraception; 9.Patients with severe mental or neurological disorders, affecting informed consent and/or the expression or observation of adverse reactions; 10.The researchers believe that the individual is not suitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of grade 3-4 neutropenia (ANC reduction); | — |
Countries
China
Contacts
Public ContactCheng Shuxia
Henan Cancer Hospital
Outcome results
None listed